MRIDIAN CLINICAL COMPANY CONTACT LOGIN GLOBAL Our Mission: To Treat and Prove What Others Can’t MRIdian® MRI-Guided Radiation Therapy – Ablative dose1 – Tight Margins1 – No implants required to see tumor1 – 5 or fewer fractions2 – No or low grade 3 toxicity2 LEARN MORE MRIdian Locator We’re Making the Invisible Visible MRIdian® Real-time tissue tracking with automated beam gating Discover MRIdian® MRIdian gives clinicians the confidence to shrink margins while escalating dose and reducing fractions. Patients have more treatment options, better treatment outcomes, reduced toxicity and improved quality of life. LEARN MORE Clinical Information Combining the latest innovations in precision radiation delivery, groundbreaking MR image guidance, and on-table adaptive therapy, MRIdian represents a new paradigm in radiation oncology. LEARN MORE Citations 1Chuong MD, Bryant J, Mittauer KE, Hall M, Kotecha R, Alvarez D, Romaguera T, Rubens M, Adamson S, Godley A, Mishra V, Luciani G, Gutierrez AN, Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy (MRgRT) with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer, Practical Radiation Oncology (2020) 2Finazzi T, Haasbeek CJA, Spoelstra FOB, Palacios MA, Admiraal MA, Bruynzeel AME, Slotman BJ, Lagerwaard FJ, Senan S, Clinical outcomes of stereotactic MR-guided adaptive radiation therapy for high-risk lung tumors International Journal of Radiation Oncology • Biology• Physics (2020); Rosenberg S. A. et al. (2018). A multi-institutional experience of MR-guided liver stereotactic body radiation therapy. Advances in Radiation Oncology, 4(1), 142-149; Rudra S. et al. (2019). Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Medicine, 8(5), 2123-2132; Henke, L., et al. (2018). Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiotherapy and Oncology, 126(3), 519-526. Henke LE, et al. Stereotactic mr-guided online adaptive radiation therapy (smart) for ultracentral thorax malignancies: Results of a phase 1 trial. Adv Radiat Oncol 2019;4:201-209; Rosenberg SA, et al. A multi-institutional experience of mr-guided liver stereotactic body radiation therapy. Adv Radiat Oncol 2019;4:142-149; Kennedy WR, Thomas MA, Stanley JA, Luo J, Ochoa LL, Clifton KK, Cyr AE, Margenthaler JA, DeWees TA, Price A, Kashani R, Green O, Zoberi I, Single Institution Phase I/II Prospective Clinical Trial of Single Fraction High Gradient Adjuvant Partial Breast Irradiation for Hormone Sensitive Stage 0-I Breast Cancer, International Journal of Radiation Oncology • Biology • Physics (2020); Bruynzeel AME, Tetar SU, Oei SS, Senan S, Haasbeek CJA, Spoelstra FOB, Piet AHM, Meijnen P, Bakker van der Jagt MAB, Fraikin T, Slotman BJ, van Moorselaar RJA, Lagerwaard FJ, A prospective single-arm phase II study of stereotactic magnetic-resonance-guided adaptive radiotherapy for prostate cancer: Early toxicity results, International Journal of Radiation Oncology • Biology • Physics (2019) Contact Us Today To Learn More CONTACT Home Old Safety Privacy Legal MR-Guided SMART Discover MRIdian MRIdian Locator Medical Affairs Bibliography About ViewRay Newsroom Investors Partner Program Careers Contact ViewRay Headquarters 2 Thermo Fisher Way Oakwood Village, OH 44146 +1 440.703.3210 Phone +1 800.417.3459 Fax West Coast Office 815 E Middlefield Rd Mountain View, CA 94043 +1 650.252.0920 Phone © 2021 VIEWRAY TECHNOLOGIES, INC. (“VIEWRAY”). ALL RIGHTS RESERVED. INTENDED FOR HEALTHCARE PROFESSIONALS ONLY. This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy ACCEPT